5 months ago
7
23andMe had all the signs of a success story. The unicorn brand became synonymous with consumer-facing genetic testing, went public, and was once valued at $6 billion.
But then, it all came tumbling down. Sales for 23AndMe kits began to fall, attempts to raise new funds hit a wall, the company struggled to find a product that would bring in recurring revenue, and it was still dealing with the fallout from a major data breach.
23andMe filed for bankruptcy and put its Source: https://mashable.com/article/23andme-sale-to-regeneron-pharmaceuticals Disclaimer of liability !!!
NEWS.SP1.RO is an automatic news aggregator. In each article, taken over by NEWS.SP1.RO with maximum 500 characters from the original article, the source name and hyperlink to the source are specified.
The acquisition of information aims to promote and facilitate access to information, in compliance with intellectual property rights, in accordance with the terms and conditions of the source.
If you are the owner of the content and do not wish to publish your materials, please contact us by email at [email protected] and the content will be deleted as soon as possible.
English (US) ·